Expert oncologists will work with Epsilogen to guide the clinical program for its lead candidate, MOv18 IgE London, 9 November 2020 – Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer...
November 9, 2020 - Press Releases